Regeneron Pharmaceuticals Inc   (REGN)
Other Ticker:  
Price: $808.5900 $7.45 0.930%
Day's High: $814.3 Week Perf: 1.11 %
Day's Low: $ 800.24 30 Day Perf: 3.98 %
Volume (M): 628 52 Wk High: $ 853.97
Volume (M$): $ 507,471 52 Wk Avg: $774.53
Open: $804.17 52 Wk Low: $668.00

 Market Capitalization (Millions $) 91,694
 Shares Outstanding (Millions) 113
 Employees 10,368
 Revenues (TTM) (Millions $) 13,097
 Net Income (TTM) (Millions $) 3,991
 Cash Flow (TTM) (Millions $) -1,345
 Capital Exp. (TTM) (Millions $) 619

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc is a biotechnology company that specializes in developing and commercializing innovative medicines for serious medical conditions. The company was established in 1988, and since then it has grown tremendously to become one of the most notable biotech companies in the world.

Regeneron's headquarters are based in Tarrytown, New York, where it has a sprawling 579-acre research and development center. The company has over 8,000 employees worldwide, including scientists, researchers, and clinicians, who work tirelessly to advance medical research and develop novel medicines.

Regeneron has a wide portfolio of products that include treatments for a range of conditions such as age-related macular degeneration, diabetic macular edema, atopic dermatitis, asthma, and cancer. The company is known for developing biologics, which are drugs that are made using living organisms. Regeneron's proprietary technology and production methods have enabled it to create highly effective and safe biologic treatments that have transformed the lives of many patients.

One of Regeneron's most well-known products is Eylea, a drug that treats age-related macular degeneration, a leading cause of blindness in older adults. Regeneron's second drug, Dupixent, is used for the treatment of moderate-to-severe atopic dermatitis in adults.

Regeneron is also active in the fight against COVID-19. The company developed a novel therapy called REGEN-COV, which is a combination of two monoclonal antibodies that have been shown to reduce hospitalization and death in COVID-19 patients. Regeneron has received approvals for this therapy from several regulatory bodies around the world and is now being widely used in the US and other countries.

In conclusion, Regeneron Pharmaceuticals Inc is a pioneering biotechnology company that is committed to developing innovative and effective treatments for serious medical conditions. The company's dedication to research, development, and patient care has made it a leader in the biotech industry and an important player in the fight against diseases.

   Company Address: 777 Old Saw Mill River Road Tarrytown 10591 NY
   Company Phone Number: 847-7000   Stock Exchange / Ticker: NASDAQ REGN
   REGN is expected to report next financial results on February 05, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Enveric Biosciences Inc

The company announced operating shortfall in the third quarter of 2023

After the leaders in the Major Pharmaceutical Preparations sector, some overlooked businesses are impending with the respective earnings. ENVB said it has realized operating shortfall of $-3.448395 million, for the third quarter of 2023.

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc Announces Revenue of $0.016 Million, Paving the Way for an Investor Opportunity

Cyclacel Pharmaceuticals Inc, a renowned biopharmaceutical company, recently released its financial results for the third quarter of 2023. While the revenue figures may seem low at $0.016 million, it is crucial to understand the context behind this decline. Despite the net deficit of $-5.982 million, larger than the previous year, strategic factors and upcoming events indicate that Cyclacel Pharmaceuticals Inc may present a significant opportunity for investors.
Revenue Insights and Future Expectations
Cyclacel Pharmaceuticals Inc's third-quarter revenue of $0.016 million reflects a temporary setback. However, it is essential to note that pharmaceutical companies often face fluctuations in revenue due to various factors such as drug development timelines, regulatory approvals, and clinical trials. These figures do not accurately reflect the long-term growth potential and overall strength of the company.

Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc Faces Fiscal Disarray as Revenue Plummets

Financial News Report: Arrowhead Pharmaceuticals Inc Announces Q4 2023 Earnings
Arrowhead Pharmaceuticals Inc has reported its financial results for the fourth quarter of 2023 earnings season, revealing a significant increase in its loss per share. The company recorded a loss of $-1.02 per share, compared to $-0.81 per share in the same quarter the previous year, and a growth in loss from $-0.96 per share from the previous quarter.
Additionally, the company's revenue for the quarter declined by -49.02% to $16.10 million, down from $31.58 million in the same quarter a year before. However, sequentially, the revenue grew by 1.719% from $15.83 million.

Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings Inc. Faces Setback with Operating Loss in Q3 2023

Pharmaceutical preparations sector advisors have started analyzing the financial performance of Lixte Biotechnology Holdings Inc for the third quarter of 2023. Despite the company not reporting any top-line figures yet, there are positive signs to signify progress. This article will outline the key facts and interpret the financial results, providing investors with a clearer understanding of Lixte Biotechnology's current standing.
Operating Loss:
Lixte Biotechnology Holdings Inc recorded an operating loss of $-1.024181 million in the third quarter of 2023. While the absence of top-line figures is noteworthy, the operating loss shows improvement compared to the same quarter in 2022, which reported a loss of $-1.478501 million. This reduction in operating loss signals positive growth and has given investors affirmation about Lixte Biotechnology's potential.

Earth Science Tech Inc

The company released Revenue of $1.92772 million, in the fiscal interval closing September 30 2023

Earth Science Tech Inc, a leading company in the science and wellness industry, has recently released its financial results for the fiscal interval closing September 30, 2023. The results indicate a significant improvement in revenue, earnings, and profit margins. Additionally, the company's stock performance has been impressive, reflecting strong investor confidence. This article will outline the key facts from the financial results and provide an overview of the context surrounding Earth Science Tech Inc's recent achievements.
Financial Results:
1. Revenue: Earth Science Tech Inc achieved revenue of $1.92772 million in the fiscal interval closing September 30, 2023. This represents a substantial increase compared to the same quarter the previous year.


Regeneron Pharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com